Each participant would complete four test days and each test day is separated by 7-10 days. At each test day the participants would complete a graded maximal exercise test (VO2max-test), a chair rise (Linear encoder) as well as measuring of basic demographic outcomes (weight, fat%,blood pressure etc.). The first test day would further include a motor (MDS-UPDRS III) and cognitive examination (MoCA), a questionnaire about quality of life (PDQ-39) and one about depression (BDI-II). Furthermore, the first test day would include two test of walking performance (6 minutes walk test and Time Up and Go). Two of the test days would be completed while the participants are off their Parkinson disease medication for at least 12 hours, while the other two test days would be completed while on their Parkinson medication. The order of the tests would be randomized. It is hypothesized that the VO2max test would be reliable and valid when participants are on medication, while off-medication would affect the reliability and validity.
Study Type
OBSERVATIONAL
Enrollment
20
Sport Science, Department of Public Health, Aarhus University
Aarhus, Denmark
VO2max (O2ml/min/kg) change
The maximal oxygen consumption during and graded exercise test. Used to asses the day to day variation between two test.
Time frame: Up to 40 days
VO2 plateau (Primary validity criterion)
Looking at the difference between the actual measure of VO2 at the end of the VO2-max test and the predicted VO2 calculated using a linear regression.
Time frame: Up to 40 days
Respiratory exchange ratio (RER) (secondary validity criterion)
The ratio between VCO2 (L/min) and VO2 (L/min)
Time frame: Up to 40 days
Blood lactate (secondary validity criterion)
Blood lactate level taken from a fingertip one minute after the VO2max has ended.
Time frame: Up to 40 days
Maximal heart rate (beats/min) (secondary validity criterion)
We would detect the maximal heart rate at the end of the test
Time frame: Up to 40 days
Rating perceived exertion (RPE) (secondary validity criterion)
Using the Borg scala, we would determine the RPE at the end of the test.
Time frame: Up to 40 days
Chair rise - maximal power output (W) change
The maximal power output measured during af chair rise (Linear Encoder). Using the change between two tests to evaluate the reliability
Time frame: Up to 40 days
Parkinson's Disease Questionnaire (PDQ-39)
A questionnaire to evaluate the quality of life with scores ranging from 0-100 (higher scores indicating worse quality of life)
Time frame: At the first test day
Beck Depression Inventory-II (BDI-II)
To evaluate depression. Scores ranges from 0-63 with higher scores indicating more severe depressive symptoms
Time frame: At the first test day
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating scale (MDS-UPDRS) III
A motor examination done by an educated assessor. Scores ranges from 0-132 with higher scores indicating more severe motor disability.
Time frame: At the first test day
6-minute walk test (6MWT)
To measure the distance, the participant is able to walk over 6 minutes using a 30 meter track.
Time frame: At the first test day
Timed up and go (TUG)
Participants have to rise from a chair, walk three meters and go back and sit on the chair again as fast as possible, without running
Time frame: At the first test day
The Montreal Cognitive Assessment (MoCA)
Participants have to complete different task using the MoCA.
Time frame: At the first test day
Weight (kg)
We would collect information about weight using bioimpedance sensor (TANITA SC220).
Time frame: Four times (one at each visit) during af 40 days period
Blood pressure (systolic/diastolic) (mmHg)
Using a blood pressure monitor to ensure that participants do not have a blood pressure above 160/110 mmHg at test day.
Time frame: Four times (one at each visit) during af 40 days period
Date of diagnosis (month and year)
Collecting information from when participants were diagnosed with Parkinson disease to detect disease duration (years)
Time frame: At first visit only
Medication
We want to know what type of medication that they use to ensure that participants fulfill the inclusion criterion
Time frame: At first visit only
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.